Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec. 16, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Dec. 13, 2019 - Puma Biotechnology Presents Interim Results of Phase II CONTROL trial of Neratinib in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS Read
- Dec. 12, 2019 - PlasmaMATCH trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer Read
- Dec. 11, 2019 - Puma Biotechnology Presents Results from the Phase II SUMMIT trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium Read
- Dec. 2, 2019 - Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer Read
- Dec. 2, 2019 - Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries Read
- Nov. 6, 2019 - Puma Biotechnology Reports Third Quarter 2019 Financial Results Read
- Nov. 5, 2019 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer Read
- Nov. 4, 2019 - Puma Biotechnology to Present at the Credit Suisse Healthcare Conference Read
- Oct. 23, 2019 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
- Oct. 3, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Oct. 2, 2019 - FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
- Sept. 25, 2019 - Puma Biotechnology to Present at Cantor Global Healthcare Conference Read
- Sept. 11, 2019 - Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to treat HER2-Positive Metastatic Breast Cancer Read
- Sept. 5, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Sept. 4, 2019 - Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer Read
- Sept. 3, 2019 - Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference Read
- Sept. 3, 2019 - FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the treatment of Breast Cancer Patients with Brain Metastases Read
- Aug. 8, 2019 - Puma Biotechnology Reports Second Quarter 2019 Financial Results Read
- Aug. 6, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- July 25, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- July 24, 2019 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read
- July 16, 2019 - Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval Read
- July 3, 2019 - Puma Biotechnology Presents Interim Results from the Biliary tract Cohort of its Phase II SUMMIT Basket trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019 Read
- July 1, 2019 - Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to treat HER2-Positive Metastatic Breast Cancer Read
- June 5, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- June 4, 2019 - Puma Biotechnology Presents Results from Phase III NALA trial of Neratinib in Patients with HER2 Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting Read
- June 2, 2019 - Puma Biotechnology Presents Interim Results of Phase II CONTROL trial of Neratinib in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting Read
- May 29, 2019 - Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference Read
- May 9, 2019 - Puma Biotechnology Reports First Quarter 2019 Financial Results Read
- May 8, 2019 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019 Read
- May 3, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- April 25, 2019 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Read
- April 9, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- April 4, 2019 - Puma Biotechnology Expands Cohorts in Phase II SUMMIT trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations Read
- April 1, 2019 - Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe Read
- March 28, 2019 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019 Read
- March 18, 2019 - Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
- March 18, 2019 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting Read
- March 14, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- March 5, 2019 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference Read
- Feb. 28, 2019 - Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results Read
- Feb. 15, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Feb. 13, 2019 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results Read
- Feb. 4, 2019 - Puma Biotechnology Announces Litigation Victory with Jury’s Decision Read
- Jan. 11, 2019 - Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada Read
- Jan. 3, 2019 - Puma Biotechnology to Present at J. P. Morgan Healthcare Conference Read
- Jan. 2, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read